GenFleet Therapeutics Announces Efficacy & Safety Result fro

GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting

SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in

Related Keywords

Thailand , Chicago , Illinois , United States , China , Candiolo , Piemonte , Italy , Shanghai , Yu Wang , Henan , American , Vanesa Gregorc , Rafael Rosell , China National Medical Products Administration , American Society Of Clinical Oncology , Candiolo Cancer Institute , Genfleet Therapeutics , Clinical Oncology , National Medical Products Administration , Chief Medical Officer , Priority Review Designation , Breakthrough Therapy Designations , Thailand Business ,